Health Sciences Acquisition Corporation (HSACU), announced the pricing of their $100 million SPAC IPO tonight and the units are expected to begin trading tomorrow, May 10th, under the symbol Nasdaq: HSACU.
Additionally, the underwriters have announced that they have fully exercised the over-allotment option to purchase an additional 1,500,000 units.
Health Sciences, which will be focusing on BioPharma and MedTech companies, will be led by Roderick Wong, MD, as President, CEO and Chairman, as well as senior members of RTW investments.
Total SPAC deal count for 2019 year-to-date is now 20 with $4.514 billion in gross proceeds raised. The offering is expected to close on or about May 14th, 2019.
Congratulations to all.
Chardan and UBS acted as joint book-running managers.
Loeb & Loeb LLP and Kirkland & Ellis LLP, were Issuer’s Counsel and Underwriter’s Counsel, respectively.
Terms Tracker for the Week Ending May 3, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. The big news this week was that SPACs finally had a new IPO price with Churchill Capital Corp. IX’s $250 million offering on Thursday. SPACs...
Real estate marketplace Opendoor (NASDAQ:OPEN) is poised to be the latest de-SPAC to take a double-digit jump on earnings as it heads towards the weekend up +10%, having spiked as high as +27% earlier in the day. The movement comes as the former Social Capital II target reported progress towards profitability despite a high rates...
At the SPAC of Dawn Coinbase (NASDAQ:COIN) notched a surprise profit of over $1.5 billion in the first quarter of 2024, well exceeding estimates, demonstrating the powerful effect of publicly traded ETFs have had on crypto marketplaces since the start of the year. The result has pushed the company to bump up its own guidance...
Online casino and sports company Rush Street (NYSE:RSI) is up +18.4% in trading today on the back of a solid first quarter earnings release, bringing the company’s stock to its highest price since the second half of 2022 (currently $7.60). This makes it the latest in a line of 2020 and 2021 de-SPACs that have...
Mountain Crest V (NASDAQ:MCAG) broke a long dealmaking silence by SPACs this morning, albeit with a non-binding agreement to combine with Seoul-based diagnostic biotech firm CUBEBIO. The term sheet would give the company a $620 million pre-transaction equity value and help accelerate the rollout of CUBEBIO’s CEED-NOVUS cancer screening kit products. The company signed an...